Phosphatidylserine NDI Review for US Supplement Brands

U.S. phosphatidylserine projects often move through the early sourcing steps quickly: route selection, specification review, sample COA review, MOQ, 25 kg drum planning, import paperwork, and draft label layout. Then a narrower question appears and stops the launch file: does this exact phosphatidylserine route need New Dietary Ingredient review before the supplement goes to market?

The short answer is that phosphatidylserine NDI review should be handled as a route-specific ingredient-status and evidence workflow, not as a casual supplier yes-or-no statement. FDA says a new dietary ingredient is a dietary ingredient that was not marketed in the United States before October 15, 1994. FDA also states that there is no authoritative list of dietary ingredients marketed before that date and that manufacturers and distributors are responsible for determining whether an ingredient is an NDI and for documenting the basis for that conclusion. FDA further explains that if a required notification is not submitted, the product is adulterated as a matter of law.

That changes how buyers should work. The real question is not simply whether "phosphatidylserine" is sold somewhere in the U.S. The real question is whether the exact route under review has a defensible status file for the finished supplement project.

This article is written for U.S. supplement brands, contract manufacturers, importers, distributors, procurement managers, regulatory teams, and quality teams. It focuses on supplier qualification, NDI decision ownership, evidence routing, and launch controls. It is operational guidance, not legal advice.

Where Nutranexa is mentioned, only verified site facts are used. Nutranexa identifies the operating company as Shandong Baianrui Biopharmaceutical Co., Ltd., founded in 2013, operating a 110,000+ m2 campus, and primarily serving export markets in Europe and North America. The site provides separate buyer paths for Phosphatidylserine, Soja Phosphatidylserine, and Tournesol Phosphatidylserine, along with document-request routes through Qualité & R&D, Fabrication, and Contacter le service commercial. Those facts support supplier review, but they do not by themselves determine NDI status.

The Short Answer US Teams Need First

If your team is reviewing phosphatidylserine for a U.S. dietary supplement launch, the cleanest workable process is:

1. Lock the exact PS route, finished dosage form, and intended daily use first.
2. Decide whether the working theory is pre-1994 dietary-supplement marketing, food-supply use in the same form, or a potential NDI notification path.
3. Separate supplier evidence from the party that will legally market the finished supplement.
4. Search the public FDA NDIN list and ingredient directory as research checkpoints, not as automatic proof.
5. If a notification may be required, map the filing package and 75-day timing before artwork or launch dates are treated as fixed.
6. Close the file with one written go, hold, or escalate decision.

That is the practical distinction many teams miss. A specification, COA, or qualified importer file can support the project without answering the NDI question. FDA says manufacturers and distributors are responsible for evaluating safety and labeling before marketing. In practice, that means the finished-product marketer cannot outsource the NDI conclusion to a raw-material seller.

Why NDI Review Is Its Own Buyer Task

NDI status is not the same as import, label, or supplier approval

U.S. supplement teams often collect several files at once: prior notice planning, FDA food facility registration review, Supplement Facts routing, Proposition 65 review, and supplier COA qualification. Those are all legitimate buyer tasks, but they answer different questions.

An ingredient can have a usable import file and still have an unresolved NDI issue. A supplement label can look complete and still sit on top of an uncertain ingredient-status file. A supplier can provide current specifications, batch records, and packaging details while the marketer still lacks a documented basis for its NDI position. That is why NDI review deserves its own decision lane.

There is no official pre-1994 phosphatidylserine list to rely on

FDA's background page for industry states two points that matter immediately for phosphatidylserine buyers:

• an NDI is a dietary ingredient not marketed in the United States before October 15, 1994
• there is no authoritative list of dietary ingredients marketed in dietary supplements before that date

That means teams should stop asking for a mythical one-line certificate proving old-ingredient status. They need a route-specific evidence file instead. This is especially important for phosphatidylserine because the commercial label "PS" may hide meaningful differences in source, composition, carrier, concentration, or manufacturing path. A general phosphatidylserine record is not automatically the same thing as a soy PS or sunflower PS record for the exact form under launch review.

FDA also states that if you are unsure whether an ingredient is an NDI, you may still submit a notification. That does not mean every project should file automatically. It means uncertainty should be handled as a documented regulatory decision, not as an informal email assumption.

A Six-Step Workflow for Phosphatidylserine NDI Review

Lock the exact phosphatidylserine route and finished use first

Start with the exact sellable route. Record whether the project uses general phosphatidylserine, soy phosphatidylserine, or sunflower phosphatidylserine. Add the intended dosage form, recommended daily intake, serving count, target consumer, and whether the product will be sold only as a dietary supplement rather than as a conventional food concept.

This matters because the NDI question is tied to the ingredient and the conditions of use. FDA's 21 CFR 190.6 rule requires any premarket notification to describe the supplement or supplements that will contain the NDI, including the ingredient level and the conditions of use recommended or suggested in labeling. A buyer cannot evaluate that cleanly if the route is still drifting between multiple PS forms.

Separate supplier support from the legal marketing decision

The supplier can support the file, but the finished-product marketer owns the decision. For a Nutranexa project, that means the supplier may help with route identification, specification logic, COA examples, packaging facts, and manufacturing context, while the brand, contract manufacturer, or distributor still owns the U.S. regulatory conclusion for the finished supplement. Without that ownership split, procurement often assumes regulatory has enough, while regulatory assumes the supplier already settled the issue.

Build the status evidence file before debating conclusions

The strongest NDI reviews begin with evidence collection, not opinions. FDA's background page says manufacturers and distributors are responsible for determining whether an ingredient is an NDI and for documenting the basis for that conclusion. That supports a three-lane evidence file:

1. evidence of marketing in U.S. dietary supplements before October 15, 1994
2. evidence relevant to the food-supply and same-form analysis
3. evidence relevant to a potential NDIN if the first two lanes do not close the question

FDA's public Submitted 75-Day Premarket Notifications for New Dietary Ingredients page is useful because it provides a searchable list of publicly displayable NDINs by ingredient name, submitter, submission date, and response date. FDA's ingredient directory is also useful because it brings together FDA actions and communications for ingredients found in products marketed as dietary supplements. Neither page is a substitute for route matching, but both are legitimate research checkpoints.

If notification may be required, map the filing package early

Once the team sees that a notification may be needed, timing becomes operational, not theoretical. FDA's NDI process page states that the notification generally must include the basis on which the manufacturer or distributor has concluded that a dietary supplement containing the NDI will reasonably be expected to be safe under the conditions of use. The current FDA submission page also says notifications can be filed electronically through COSM.

The regulation at 21 CFR 190.6 requires the package to include:

• the name and complete address of the manufacturer or distributor
• the name of the new dietary ingredient
• a description of the supplement or supplements that contain it
• the ingredient level in the product
• the conditions of use recommended or suggested in labeling
• the history of use or other evidence of safety
• supporting reprints or copies of published references
• English translations for foreign-language materials
• the submitter's signature

The same regulation also states that the filing must be made at least 75 days before interstate marketing, substantive additional information can reset the filing date, FDA keeps the notification confidential for 90 days after filing, and failure of FDA to respond does not mean the ingredient is safe or not adulterated. If a notification path is possible, do not wait until labels, production slots, and customer launch dates are already locked.

Keep the NDI file aligned with the finished supplement record

An NDI review can become internally inconsistent if the ingredient file says one thing and the finished supplement says another. The route, daily use, dosage form, and responsible marketer should stay aligned across the NDI file, the Supplement Facts review, formulation records, supplier approval notes, and any downstream customer questionnaire.

That is especially important when teams change:

• the PS source route
• the daily serving
• the dosage form
• the target consumer
• the co-manufacturer or brand owner

Each of those changes can reopen an earlier conclusion. A route-specific decision that looked defensible for one supplement configuration may not carry cleanly into another.

Close with a go, hold, or escalate decision

The final step is to close the review in writing:

• Go: the exact route is stable, the evidence file supports the position, and launch timing matches the team's conclusion.
• Hold: the project may still move forward later, but the evidence is too thin or too mismatched to support a clean launch now.
• Escalate: the team needs outside regulatory or legal review, a submitter decision, or a formal NDIN path before anyone treats the project as market-ready.

This closeout matters because the NDI question often resurfaces late, usually when the first commercial batch or customer launch calendar is already moving. One written status line is more useful than a long chain of scattered comments.

A Practical Evidence Matrix for PS NDI Review

Need Route-Specific PS Documents Before US Launch?

If your U.S. launch file still describes only "phosphatidylserine" without a stable source route, finished daily use, and document-revision trail, pause before treating the ingredient as market-ready. Use Nutranexa's contact page to request the current route-specific specification path, COA path, packaging baseline, and manufacturing-support context for the exact phosphatidylserine route under review. The supplier can support the ingredient file; your U.S. marketer still owns the NDI conclusion.

Common NDI Mistakes to Prevent

1. Treating a supplier email or brochure as if it closes the NDI question.
2. Assuming any public reference to phosphatidylserine proves the exact route was marketed in U.S. supplements before October 15, 1994.
3. Mixing food-supply evidence, import paperwork, and finished-label review into one uncontrolled folder.
4. Using a public NDIN or ingredient-directory entry as if it automatically covers another company's product.
5. Forgetting that the 75-day timeline runs from filing, and that substantive amendments can reset the filing date.
6. Treating FDA silence as product approval.
7. Letting the formula, serving, or source route change after the NDI position was documented without reopening the file.

The practical fix is narrow: keep one question at the center of the review. What is the exact phosphatidylserine route, what evidence supports its status for this supplement use, and who owns the final U.S. marketing decision?

How Verified Nutranexa Facts Fit This Workflow

For buyers evaluating Nutranexa, several verified site facts help organize the NDI file correctly. The site separates Phosphatidylserine, Soja Phosphatidylserine, and Tournesol Phosphatidylserine, which helps teams keep route identity stable instead of hiding multiple routes under one vague PS label.

Nutranexa also states that the company was founded in 2013, operates a 110,000+ m2 campus, and primarily serves Europe and North America. Public request paths through Qualité & R&D, Fabrication, and Contacter le service commercial, plus the published 25 kg MOQ et 25 kg net par fût baseline for PS, help teams collect supplier evidence efficiently. Those facts support qualification and launch planning, but they do not replace the NDI review.

Sources

• FDA: Dietary Supplements
• FDA: New Dietary Ingredient (NDI) Notification Process
• FDA: New Dietary Ingredients in Dietary Supplements - Background for Industry
• FDA: How to Submit Notifications for a New Dietary Ingredient
• FDA: Submitted 75-Day Premarket Notifications for New Dietary Ingredients
• FDA: Information on Select Dietary Supplement Ingredients and Other Substances
• FDA: Dietary Supplement Labeling Guide, Chapter VII. Premarket Notification of New Dietary Ingredients
• eCFR: 21 CFR 190.6 Requirement for premarket notification
• U.S. Code: 21 U.S.C. 350b New dietary ingredients

FAQ

Does phosphatidylserine automatically avoid NDI notification in the United States?

No. FDA says manufacturers and distributors are responsible for determining whether an ingredient is an NDI and for documenting the basis for that conclusion. The answer depends on the exact route, evidence file, and intended use.

Is a supplier COA or specification enough for phosphatidylserine NDI review?

No. They help define the route under review, but they do not by themselves prove pre-1994 marketing, same-form food-supply status, or satisfaction of a notification obligation.

If a public NDIN exists for phosphatidylserine, does it automatically cover my product?

Not automatically. Public NDIN records are research checkpoints. Buyers still need to compare exact ingredient identity, source, form, conditions of use, and marketer role before treating another filing as relevant.

Does FDA silence after an NDI filing mean the product is approved?

No. FDA's regulation states that failure of the agency to respond does not constitute a finding that the ingredient or supplement is safe or not adulterated.

What should a buyer request from Nutranexa for a U.S. NDI review?

Request the exact route-specific specification path, COA path, source description, packaging baseline, and document-revision context for the quoted route, then align those supplier facts with your own U.S. ingredient-status review.

Conclusion

Phosphatidylserine NDI review becomes manageable when U.S. teams stop treating it as a generic supplier question and start treating it as a route-specific ingredient-status file.

The strongest workflow is practical: lock the exact PS route, separate supplier support from the marketer's legal responsibility, build the evidence file before debating conclusions, map the 75-day filing path early if needed, keep the NDI record aligned with the finished supplement, and close with one written decision. That process reduces a common launch failure: the sourcing file looks complete, but nobody can show how the U.S. premarket position was actually reached.

Étapes suivantes recommandées

• Passez en revue le Phosphatidylserine page produit.
• Comparer Soy PS et Sunflower PS.
• Vérifier preuve de fabrication et Qualité & R&D.